Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.

Kelaidi, C; Rollot, F; Park, S; Tulliez, M; Christoforov, B; Calmus, Y; Podevin, P; Bouscary, D; Sogni, P; Blanche, P; Dreyfus, F

Kelaidi, C; Rollot, F; Park, S; Tulliez, M; Christoforov, B; Calmus, Y; Podevin, P; Bouscary, D; Sogni, P; Blanche, P; Dreyfus, F.

Affiliation

Kelaidi C; 1Department of Hematology, Hôpital Cochin, Université Paris V, Assistance Publique Hôpitaux de Paris, Paris, France.

Leukemia ; 18(10): 1711-6, 2004 Oct.

Article in En | MEDLINE | ID: mdl-15284859

Subject(s)

Antiviral Agents/therapeutic use; Hepacivirus/pathogenicity; Hepatitis C/drug therapy; Lymphoma, B-Cell/virology; Adult; Aged; Drug Therapy, Combination; Female; Hepacivirus/genetics; Hepacivirus/isolation & purification; Hepatitis C/complications; Hepatitis C/virology; Humans; Interferon-alpha/therapeutic use; Lymphoma, B-Cell/complications; Lymphoma, B-Cell/drug therapy; Male; Middle Aged; Prospective Studies; Retrospective Studies; Ribavirin/therapeutic use; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Lymphoma, B-Cell / Hepatitis C / Hepacivirus Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Year: 2004 Document type: Article

Search on Google

XML

PubMed Links